Fentanyl Recall: Wells Pharma NDC 73702-202-15
Announced 2026-05-06 · FDA
The recall covers fentanyl citrate injectable solution in 0.9% sodium chloride, 50 mcg per 5 mL. It involves 50 syringes distributed nationwide in the United States. Lot 020226202150202 expires 05/05/2026 and the recall is due to cGMP deviations.
| Brand | Wells Pharma of Houston LLC |
|---|---|
| Product | fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15. |
| Reason | cGMP deviations. |
| Severity | moderate |
| Units affected | 4975 |
| Distribution | U.S. Nationwide. |
| Agency | FDA |
| Recall / campaign no. | Lot 020226202150202, Exp Date 05/05/2026. |
WHAT YOU SHOULD DO
- Do not use or administer the recalled product.
- Contact Wells Pharma or your healthcare provider for instructions on return or disposal.
- Follow the guidance provided by your healthcare provider or retailer for obtaining a replacement or refund.
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.